Á¤»ó¼³
À¯¹æ°©»ó¼±¾Ï¼¾ÅÍÀå
¼Ò
¼Ó
: ºÐ´çÂ÷º´¿ø
Àü¹®ºÐ¾ß : À¯¹æ
Á÷
ˤ
: ±³¼ö(À¯¹æ°©»ó¼±¾Ï¼¾ÅÍÀå)
¸Þ
ÀÏ
:
ºñ°ø°³
Àü
È
:
1577-4488
ÆÑ
½º
:
ÁÖ
¼Ò
:
°æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßž·Î 59
ȨÆäÀÌÁö:
ÅǸ޴º
ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£
±¸ºÐ
Á¦¸ñ
´Ù¿î·Îµå
146
ÇØ¿Ü
Lymph node ratio and pN staging in patients with node-positive breast cancer: a report from the Korean breast cancer society : BREAST CANCER RESEARCH AND TREATMENT : 201111
145
ÇØ¿Ü
Expression of Nuclear Receptor DAX-1 and Androgen Receptor in Human Breast Cancer : JOURNAL OF SURGICAL ONCOLOGY : 201106
144
±¹³»
Status and prospect of workforce requirement for surgery in republic of Korea : JOURNAL OF THE KOREAN SURGICAL SOCIETY(´ëÇÑ¿Ü°úÇÐȸÁö / 2013³â±îÁö ¹ßÇà) : 201112
143
ÇØ¿Ü
Performing Contralateral Central Lymph Node Dissection in Papillary Thyroid Carcinoma: A Decision Approach : THYROID : 2011.08
142
ÇØ¿Ü
Measurement of ER and PR status in breast cancer using the QuantiGene2.0 assay : PATHOLOGY : 2011.04
141
ÇØ¿Ü
Role of Sonographic Elastography in the Differential Diagnosis of Axillary Lymph Nodes in Breast Cancer : JOURNAL OF ULTRASOUND IN MEDICINE : 2011.04
140
ÇØ¿Ü
Bilateral primary breast lymphoma : CHINESE MEDICAL JOURNAL : 2010.06
139
±¹³»
"Branched-chain Assay for ER, PR, and HER2 RNA levels is a useful adjunct in the evaluation of ER, PR, and HER2 in breast cancer" : JOURNAL OF BREAST CANCER(2008³â 9¿ù ÀÌÈÄ °ÔÀç) : 2010.09
138
ÇØ¿Ü
Relationship between age at diagnosis and outcome of premenopausal breast cancer: age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer : BREAST CANCER RESEARCH AND TREATMENT : 2010.01
137
ÇØ¿Ü
Genomic alterations of primary tumor and blood in invasive ductal carcinoma of breast : WORLD JOURNAL OF SURGICAL ONCOLOGY : 2010.04
1
2
3
4
5
6
7
8
9
10
Copyright ¨Ï chamc, All rights reserved.
ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à
Àüȹ®ÀÇ
°³²Â÷º´¿ø 02.3468.3000
ºÐ´çÂ÷º´¿ø 031.780.5000
Â÷¿ò 02.3015.5300
±¸¹ÌÂ÷º´¿ø 054.450.9700
´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
°³²°ÇÁø¼¾ÅÍ 02.2191.3900
ºÐ´çÁ¾ÇÕ°Ç°ÁõÁø¼¾ÅÍ 031.780.5940
½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729